An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe Plaque Psoriasis

Purpose

The purpose of this study is to investigate the experimental medication BMS-986165 compared to placebo and a currently available treatment in participants with moderate to severe plaque psoriasis.

Condition

  • Psoriasis

Eligibility

Eligible Ages
Over 18 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Plaque psoriasis for at least 6 months - Moderate to severe disease - Candidate for phototherapy or systemic therapy

Exclusion Criteria

  • Other forms of psoriasis - History of recent infection - Prior exposure to BMS-986165 or active comparator Other protocol defined inclusion/exclusion criteria could apply

Study Design

Phase
Phase 3
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Treatment
Masking
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
BMS-986165
BMS-986165 oral administration
  • Drug: BMS-986165
    Specified dose on specified days
Placebo Comparator
Placebo
Placebo oral administration
  • Other: Placebo
    Specified dose on specified days
Active Comparator
Active comparator
Active comparator oral administration
  • Drug: Apremilast
    Specified dose on specified days

More Details

Status
Completed
Sponsor
Bristol-Myers Squibb

Study Contact